Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Non Operating Income (2019 - 2024)

Eton Pharmaceuticals' Non Operating Income history spans 6 years, with the latest figure at -$1.1 million for Q4 2024.

  • On a quarterly basis, Non Operating Income fell 7025.0% to -$1.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$1.2 million, a 340.76% decrease, with the full-year FY2025 number at -$3.7 million, down 206.69% from a year prior.
  • Non Operating Income hit -$1.1 million in Q4 2024 for Eton Pharmaceuticals, down from -$8000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for ETON hit a ceiling of $676000.0 in Q2 2023 and a floor of -$1.1 million in Q4 2024.
  • Historically, Non Operating Income has averaged -$149900.0 across 5 years, with a median of -$171000.0 in 2020.
  • Biggest five-year swings in Non Operating Income: skyrocketed 410.09% in 2023 and later crashed 7025.0% in 2024.
  • Tracing ETON's Non Operating Income over 5 years: stood at -$267000.0 in 2020, then fell by 3.0% to -$275000.0 in 2021, then soared by 45.45% to -$150000.0 in 2022, then skyrocketed by 89.33% to -$16000.0 in 2023, then crashed by 7025.0% to -$1.1 million in 2024.
  • Business Quant data shows Non Operating Income for ETON at -$1.1 million in Q4 2024, -$8000.0 in Q3 2024, and -$52000.0 in Q2 2024.